Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

艾塞那肽 赛马鲁肽 医学 2型糖尿病 内科学 随机对照试验 胃肠病学 杜拉鲁肽 糖尿病 临床终点 泌尿科 内分泌学 利拉鲁肽
作者
Andrew Ahmann,Matthew Capehorn,G. Charpentier,Francesco Dotta,Elena Henkel,Ildiko Lingvay,Anders G. Holst,Miriam Annett,Vanita R. Aroda
出处
期刊:Diabetes Care [American Diabetes Association]
卷期号:41 (2): 258-266 被引量:465
标识
DOI:10.2337/dc17-0417
摘要

OBJECTIVE To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA1c at week 56. RESULTS Mean HbA1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] –0.62% [95% CI –0.80, –0.44] [–6.78 mmol/mol (95% CI –8.70, –4.86)]; P < 0.0001 for noninferiority and superiority). Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD –3.78 kg [95% CI –4.58, –2.98]; P < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%). Both treatments had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER–treated subjects (33.3%); injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%). CONCLUSIONS Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
persist发布了新的文献求助10
1秒前
1秒前
surfer363发布了新的文献求助10
3秒前
xixi发布了新的文献求助10
3秒前
量子星尘发布了新的文献求助10
3秒前
ZZ发布了新的文献求助10
4秒前
4秒前
苍蝇搓手完成签到,获得积分10
5秒前
znn发布了新的文献求助10
5秒前
大罗完成签到,获得积分10
5秒前
5秒前
初雪平寒完成签到,获得积分10
6秒前
7秒前
情怀应助平淡冬亦采纳,获得10
7秒前
哈哈哈完成签到 ,获得积分20
7秒前
8秒前
木子完成签到 ,获得积分10
9秒前
chengzhenfa发布了新的文献求助10
9秒前
DennisLiberta完成签到,获得积分10
9秒前
阮楷瑞发布了新的文献求助10
10秒前
镜花水月发布了新的文献求助20
11秒前
小宝完成签到,获得积分10
11秒前
chenmou发布了新的文献求助10
12秒前
12秒前
小天才发布了新的文献求助10
12秒前
阿银完成签到 ,获得积分10
12秒前
surfer363完成签到,获得积分10
13秒前
13秒前
共享精神应助炙热的发带采纳,获得10
14秒前
Alerina发布了新的文献求助10
14秒前
15秒前
YHW19发布了新的文献求助10
16秒前
17秒前
校长发布了新的文献求助10
17秒前
18秒前
Tao完成签到,获得积分10
18秒前
林灵凌关注了科研通微信公众号
19秒前
欣喜面包完成签到,获得积分10
19秒前
20秒前
元谷雪发布了新的文献求助30
20秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974463
求助须知:如何正确求助?哪些是违规求助? 3518823
关于积分的说明 11196212
捐赠科研通 3255008
什么是DOI,文献DOI怎么找? 1797655
邀请新用户注册赠送积分活动 877052
科研通“疑难数据库(出版商)”最低求助积分说明 806130